Cover Image
市場調查報告書

X染色體脆折症候群:開發中產品分析

Fragile X Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200946
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
Back to Top
X染色體脆折症候群:開發中產品分析 Fragile X Syndrome - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 117 Pages
簡介

X染色體脆折症候群特徵是遺傳性的精神遲緩,伴隨X染色體的部分變動,以及健康狀態上受肉體、智力上的限制。病因之一是FMR1遺傳基因的變異。行動方面的症狀有爬行、步行、扭轉相關遲緩,及拍手、咬手,過度、衝動的行動,精神遲緩,言詞、語言遲緩,迴避目光接觸等傾向。肉體的徵兆,有扁平足,關節鬆動,肌肉張力低下,前額、耳朵巨大(也包含下巴肥大),長臉等。日常生活的獨立性改善上,復建是最好的方法。

本報告提供全球各國的X染色體脆折症候群治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品的一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等。

簡介

  • 調查範圍

X染色體脆折症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

X染色體脆折症候群:企業開發中的治療藥

X染色體脆折症候群:大學/機關研究中的治療藥

X染色體脆折症候群:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

X染色體脆折症候群:企業開發中的產品

X染色體脆折症候群:大學/機關研究中的產品

X染色體脆折症候群的治療藥的開發企業

  • Aelis Farma SAS
  • Alcobra Ltd
  • AMO Pharma Limited
  • Confluence Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Marinus Pharmaceuticals, Inc.
  • MI.TO. Technology S.r.L.
  • Neuren Pharmaceuticals Limited
  • Ovid Therapeutics Inc.
  • Sage Therapeutics, Inc.
  • Zynerba Pharmaceuticals, Inc.

X染色體脆折症候群:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

X染色體脆折症候群:最近的開發平台趨勢

X染色體脆折症候群:暫停中的計劃

X染色體脆折症候群:開發中止的產品

X染色體脆折症候群:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8479IDB

Summary

Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2016', provides an overview of the Fragile X Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
  • The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fragile X Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Fragile X Syndrome - Overview
    • Pipeline Products for Fragile X Syndrome - Comparative Analysis
  • Fragile X Syndrome - Therapeutics under Development by Companies
  • Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Fragile X Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fragile X Syndrome - Products under Development by Companies
  • Fragile X Syndrome - Products under Investigation by Universities/Institutes
  • Fragile X Syndrome - Companies Involved in Therapeutics Development
    • Aelis Farma SAS
    • Alcobra Ltd
    • AMO Pharma Limited
    • Anavex Life Sciences Corp.
    • Confluence Pharmaceuticals LLC
    • DRI Biosciences Corporation
    • Eli Lilly and Company
    • GlaxoSmithKline Plc
    • GW Pharmaceuticals Plc
    • Kareus Therapeutics, SA
    • Marinus Pharmaceuticals, Inc.
    • Neuren Pharmaceuticals Limited
    • Neuron Biopharma SA
    • Ovid Therapeutics Inc.
    • Sage Therapeutics, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Fragile X Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acamprosate calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMO-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bryostatin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cercosporamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flindokalner - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gaboxadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JRP-655 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KU-046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metadoxine ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNZ-2591 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGE-872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-278 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TC-2153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trofinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fragile X Syndrome - Dormant Projects
  • Fragile X Syndrome - Discontinued Products
  • Fragile X Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
      • Jun 28, 2016: Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
      • Jun 27, 2016: Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
      • Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
      • Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders
      • Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
      • Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
      • Jun 07, 2016: AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome
      • Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
      • Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
      • Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
      • Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
      • Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
      • Dec 07, 2015: Neuren's trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome
      • Nov 30, 2015: Neuren receives grant of composition patent in Europe for NNZ-2591
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fragile X Syndrome, H2 2016
  • Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Fragile X Syndrome - Pipeline by Aelis Farma SAS, H2 2016
  • Fragile X Syndrome - Pipeline by Alcobra Ltd, H2 2016
  • Fragile X Syndrome - Pipeline by AMO Pharma Limited, H2 2016
  • Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Fragile X Syndrome - Pipeline by DRI Biosciences Corporation, H2 2016
  • Fragile X Syndrome - Pipeline by Eli Lilly and Company, H2 2016
  • Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Fragile X Syndrome - Pipeline by Kareus Therapeutics, SA, H2 2016
  • Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
  • Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2016
  • Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc., H2 2016
  • Fragile X Syndrome - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fragile X Syndrome - Dormant Projects, H2 2016
  • Fragile X Syndrome - Dormant Projects (Contd..1), H2 2016
  • Fragile X Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Fragile X Syndrome, H2 2016
  • Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top